Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 75196 | 4.39 |
09:34 ET | 63147 | 4.375 |
09:36 ET | 40077 | 4.365 |
09:38 ET | 13700 | 4.39 |
09:39 ET | 3055 | 4.41 |
09:41 ET | 7586 | 4.435 |
09:43 ET | 22205 | 4.45 |
09:45 ET | 29919 | 4.4857 |
09:48 ET | 12415 | 4.49 |
09:50 ET | 34275 | 4.485 |
09:52 ET | 7593 | 4.47 |
09:54 ET | 35872 | 4.47 |
09:56 ET | 46422 | 4.44 |
09:57 ET | 11594 | 4.44 |
09:59 ET | 8494 | 4.45 |
10:01 ET | 23888 | 4.4433 |
10:03 ET | 14587 | 4.45 |
10:06 ET | 15182 | 4.45 |
10:08 ET | 90368 | 4.425 |
10:10 ET | 15845 | 4.445 |
10:12 ET | 7988 | 4.445 |
10:14 ET | 10633 | 4.4401 |
10:15 ET | 2326 | 4.445 |
10:17 ET | 2895 | 4.445 |
10:19 ET | 22228 | 4.445 |
10:21 ET | 25695 | 4.435 |
10:24 ET | 10850 | 4.41 |
10:26 ET | 14157 | 4.425 |
10:28 ET | 25069 | 4.4289 |
10:30 ET | 8573 | 4.415 |
10:32 ET | 38337 | 4.425 |
10:33 ET | 16337 | 4.42 |
10:35 ET | 48667 | 4.425 |
10:37 ET | 61435 | 4.43 |
10:39 ET | 3037 | 4.44 |
10:42 ET | 8133 | 4.435 |
10:44 ET | 8912 | 4.435 |
10:46 ET | 16040 | 4.43 |
10:48 ET | 7606 | 4.445 |
10:50 ET | 29982 | 4.44 |
10:51 ET | 10450 | 4.43 |
10:53 ET | 5538 | 4.4251 |
10:55 ET | 5788 | 4.42 |
10:57 ET | 66077 | 4.4 |
11:00 ET | 35082 | 4.41 |
11:02 ET | 6967 | 4.405 |
11:04 ET | 12550 | 4.405 |
11:06 ET | 4095 | 4.415 |
11:08 ET | 2771 | 4.41 |
11:09 ET | 35035 | 4.4042 |
11:11 ET | 970 | 4.405 |
11:13 ET | 1931 | 4.41 |
11:15 ET | 2258 | 4.405 |
11:18 ET | 63728 | 4.3842 |
11:20 ET | 11438 | 4.385 |
11:22 ET | 10885 | 4.37 |
11:24 ET | 8866 | 4.38 |
11:26 ET | 16082 | 4.385 |
11:27 ET | 11500 | 4.385 |
11:29 ET | 9654 | 4.375 |
11:31 ET | 15311 | 4.36 |
11:33 ET | 5074 | 4.36 |
11:36 ET | 1459 | 4.36 |
11:38 ET | 45981 | 4.365 |
11:40 ET | 22401 | 4.38 |
11:42 ET | 4875 | 4.375 |
11:44 ET | 14106 | 4.36 |
11:45 ET | 1796 | 4.36 |
11:47 ET | 5928 | 4.3601 |
11:49 ET | 20239 | 4.36 |
11:51 ET | 4251 | 4.36 |
11:54 ET | 15036 | 4.3601 |
11:56 ET | 30864 | 4.365 |
11:58 ET | 27585 | 4.375 |
12:00 ET | 7992 | 4.37 |
12:02 ET | 15239 | 4.375 |
12:03 ET | 18582 | 4.375 |
12:05 ET | 20835 | 4.391 |
12:07 ET | 2018 | 4.395 |
12:09 ET | 1991 | 4.4 |
12:12 ET | 2406 | 4.395 |
12:14 ET | 54727 | 4.4 |
12:16 ET | 15572 | 4.395 |
12:18 ET | 12999 | 4.39 |
12:20 ET | 5700 | 4.385 |
12:21 ET | 15555 | 4.3901 |
12:23 ET | 15361 | 4.385 |
12:25 ET | 1500 | 4.385 |
12:27 ET | 107753 | 4.405 |
12:30 ET | 3200 | 4.4 |
12:32 ET | 21385 | 4.4 |
12:34 ET | 4862 | 4.405 |
12:36 ET | 3371 | 4.4 |
12:38 ET | 30099 | 4.395 |
12:39 ET | 8550 | 4.395 |
12:41 ET | 3000 | 4.395 |
12:43 ET | 4497 | 4.39 |
12:45 ET | 4500 | 4.395 |
12:48 ET | 5559 | 4.395 |
12:50 ET | 3820 | 4.395 |
12:52 ET | 3995 | 4.395 |
12:54 ET | 1876 | 4.395 |
12:56 ET | 2000 | 4.395 |
12:57 ET | 13629 | 4.395 |
12:59 ET | 14890 | 4.39 |
01:01 ET | 6962 | 4.39 |
01:03 ET | 5328 | 4.395 |
01:06 ET | 1427 | 4.395 |
01:08 ET | 4570 | 4.39 |
01:10 ET | 1670 | 4.395 |
01:12 ET | 2702 | 4.395 |
01:14 ET | 36131 | 4.395 |
01:15 ET | 5056 | 4.39 |
01:17 ET | 65940 | 4.395 |
01:19 ET | 500 | 4.395 |
01:21 ET | 27885 | 4.405 |
01:24 ET | 1800 | 4.41 |
01:26 ET | 2300 | 4.405 |
01:28 ET | 9127 | 4.4 |
01:30 ET | 2301 | 4.405 |
01:32 ET | 2303 | 4.4 |
01:33 ET | 22582 | 4.4 |
01:35 ET | 20041 | 4.405 |
01:37 ET | 5565 | 4.405 |
01:39 ET | 28389 | 4.405 |
01:42 ET | 5914 | 4.405 |
01:44 ET | 2168 | 4.405 |
01:46 ET | 1900 | 4.4 |
01:48 ET | 27008 | 4.43 |
01:50 ET | 1290 | 4.43 |
01:51 ET | 34956 | 4.415 |
01:53 ET | 10727 | 4.425 |
01:55 ET | 1200 | 4.43 |
01:57 ET | 3907 | 4.425 |
02:00 ET | 1305 | 4.42 |
02:02 ET | 17487 | 4.415 |
02:04 ET | 1600 | 4.415 |
02:06 ET | 5700 | 4.415 |
02:08 ET | 4289 | 4.415 |
02:09 ET | 4979 | 4.42 |
02:11 ET | 2700 | 4.42 |
02:13 ET | 32884 | 4.405 |
02:15 ET | 57922 | 4.405 |
02:18 ET | 2924 | 4.405 |
02:20 ET | 11004 | 4.39 |
02:22 ET | 1000 | 4.395 |
02:24 ET | 13916 | 4.4 |
02:26 ET | 195557 | 4.425 |
02:27 ET | 42883 | 4.425 |
02:29 ET | 4100 | 4.43 |
02:31 ET | 22495 | 4.435 |
02:33 ET | 9050 | 4.43 |
02:36 ET | 3800 | 4.435 |
02:38 ET | 1300 | 4.435 |
02:40 ET | 1500 | 4.435 |
02:42 ET | 2650 | 4.435 |
02:44 ET | 20505 | 4.445 |
02:45 ET | 23130 | 4.435 |
02:47 ET | 31747 | 4.44 |
02:49 ET | 43531 | 4.445 |
02:51 ET | 12595 | 4.445 |
02:54 ET | 2700 | 4.445 |
02:56 ET | 4122 | 4.45 |
02:58 ET | 5125 | 4.445 |
03:00 ET | 2025 | 4.445 |
03:02 ET | 13881 | 4.45 |
03:03 ET | 9862 | 4.45 |
03:05 ET | 57157 | 4.45 |
03:07 ET | 1800 | 4.45 |
03:09 ET | 17199 | 4.46 |
03:12 ET | 6100 | 4.455 |
03:14 ET | 4100 | 4.455 |
03:16 ET | 34095 | 4.455 |
03:18 ET | 121057 | 4.4651 |
03:20 ET | 16595 | 4.465 |
03:21 ET | 19907 | 4.465 |
03:23 ET | 96359 | 4.46 |
03:25 ET | 16970 | 4.465 |
03:27 ET | 249712 | 4.47 |
03:30 ET | 3800 | 4.47 |
03:32 ET | 12775 | 4.465 |
03:34 ET | 12932 | 4.465 |
03:36 ET | 47380 | 4.48 |
03:38 ET | 34894 | 4.475 |
03:39 ET | 9091 | 4.47 |
03:41 ET | 45268 | 4.465 |
03:43 ET | 20705 | 4.465 |
03:45 ET | 22410 | 4.465 |
03:48 ET | 101419 | 4.44 |
03:50 ET | 25542 | 4.44 |
03:52 ET | 84279 | 4.445 |
03:54 ET | 34152 | 4.44 |
03:56 ET | 234820 | 4.45 |
03:57 ET | 149436 | 4.46 |
03:59 ET | 906783 | 4.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.8x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.3x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.8x | --- |
MoonLake Immunotherapeutics | 2.6B | -55.6x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.2x | --- |
Agios Pharmaceuticals Inc | 2.5B | -6.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.8x |
Price/Sales (TTM) | 5,155.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.